Autopsy report · NCT01084369

Effect of Testosterone on Endothelial Function and Microcirculation in Type 2 Diabetic Patients With Hypogonadism

“Withdrawal of sponsorship”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 years 7 months before it started.
• Ran for about 11 months before it stopped.
• 22 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 4

Sponsor

Tameside Hospital NHS Foundation Trust

Sponsor type

University, hospital or other

Conditions

Type 2 Diabetes; Hypogonadism

Interventions

Testosterone

Participants

22

Sites

2

Countries

United Kingdom

Trials that died the same way

• An Exploratory Investigation to Assess Changes in Quality of Life for Individuals With Type 2 Diabetes After Taking a Meal-replacement Shake.
  “Sponsor withdrawn” (89% match in meaning)
• BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL
  “Withdrawal of sponsor support” (89% match in meaning)
• Study of Atiprimod Treatment for Patients With Advanced Cancer
  “Sponsor Withdrew” (88% match in meaning)
• BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer
  “Withdrawn by sponsor” (88% match in meaning)
• Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma
  “Sponsor withdrew support” (84% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.